Provectus Biopharmaceuticals, Inc. announced that data from preclinical research by the University of Calgary on oral administration of Provectus?s pharmaceutical-grade rose bengal for the treatments of solid tumor cancers were published in the open access journal of oncology Cancers. This work has been part of research conducted by Aru Narendran, M.D., Ph.D., professor in the departments of Pediatrics, Oncology, and Biochemistry & Molecular Biology, and members of the Narendran Lab at the University of Calgary?s Cumming School of Medicine in Calgary, Alberta, Canada. The Narendran Lab provided preclinical proof-of-concept data supporting the efficacy of Provectus?s rose bengal in a panel of adult solid tumors.

The Lab identified that the Company?s rose bengal downregulated WNK1 and Wnt signaling. In mice, the Narendran Lab also confirmed the clinical utility of Provectus?s rose bengal by intratumoral (aka intralesional) administration and demonstrated potential utility by oral administration.